Category Archives: rapid learning health systems

The business case for value-based care

  •  value-based payments will come into the US in the next 5-10 years
  • payments will be based on conditions, not treatments
  • e.g. current c-section rates are highly variable, due to the way fees are paid, not their actual value

 

http://www.healthleadersmedia.com/print/COM-301451/Building-the-Business-Case-for-ValueBased-Care

Building the Business Case for Value-Based Care

John Commins, for HealthLeaders Media , February 26, 2014

 

Harold D. Miller, president and CEO of the Center for Healthcare Quality and Payment Reform, discusses a fundamental barrier to shifting payment models in healthcare: Some providers mistakenly think all they have to do is tweak existing fee-for-service billing structures without understanding what drives costs in the underlying payment system.

Harold D. MillerHarold D. Miller, President and CEO
Center for Healthcare Quality
and Payment Reform

The shift away from volume-based, fee-for-service billing towards value-based reimbursements is gaining momentum and will be largely in place over the next few years. And yet a surprising number of healthcare providers really don’t grasp the details of how value-based reimbursements work.

Harold D. Miller, president and CEO of the non-profit Center for Healthcare Quality and Payment Reform, says many providers mistakenly believe that all they have to do is tweak existing fee-for-service billing structures without identifying potential savings or understanding what drives costs in the underlying payment system.

Miller, the author of a Robert Wood Johnson Foundation-funded report called Making the Business Care for Payment and Delivery Reform, spoke with me this week about what providers must do to build an effective business case for value-based care. The following is an edited transcript.

HLM: Where are we on the fee-for-service/value-based care timeline?

Miller: It could be the dominant model within the next five to 10 years, but it is a matter of how quickly physicians and in particular physicians in hospitals meet with the purchasers of care— the employers— to work that out. It’s about how soon both side come together and create the win, win, win that is good for patients, providers, and purchasers.

HLM: What are the stumbling blocks on the road to value-based care?

Miller: Most health plans and Medicare are trying to change the way care is delivered and reduce costs by piling on pay for performance and shared savings on top of fee-for-service. The problem is that if you don’t change the underlying payment system, you don’t change the incentives and the barriers that it creates.

For example, one of the best ways to keep people with chronic disease healthier and out of the hospital is for a physician practice to hire a nurse to educate and encourage patients to call when they have a problem. The problem is that doctors don’t get paid for nurses and they don’t get paid for answering phone calls. So practices are forced to lose money under fee-for-service to deliver better care, even though it would actually save money by keeping the patients out of the hospital.

 

HLM: Is value-based healthcare a particularly challenging sector?

Miller: Every patient is different, but on the other hand, how do health insurance companies operate? The law of large numbers says that on average, patients are fairly similar. You don’t have to deliver the exact same treatment to everybody to estimate on average what it is going to be like.

If you get the unusually expensive case—the patient who is an outlier with unique health problems— that is what insurance is for.

On the other hand, saying ‘We shouldn’t be giving an MRI to everyone who comes in with lower back pain. Most of them should probably go to physical therapy first.’ That is something you can do across a broad number of patients. That is going to save money on average and probably be better for the patients.

HLM: Is there common ground for fee-for-service and value-based models that providers can build on?

Miller: A lot of the payment reforms that are being done actually build on fee-for-service. The idea is you don’t just leave it in place and try to pile something on top. The problem with fee-for-service now is that it says you get paid the exact same amount to do something whether you do it well or poorly and whether or not [or whether] there are complications or infections that occur. And in fact you may get paid more.

But you don’t fix fee-for-service by sticking little penalties or bonuses on top. You have to change the fundamental way it is delivered.

For example, for patients who have health problems, we are looking at payments based on the patient’s condition and not based on exactly the procedure you used. A good example is delivering a baby. You get paid more to do a caesarian section than you get paid than a vaginal delivery. Yet the vaginal delivery takes longer, and is better for the mother and the baby.

So why do we now have a 33% C-section rate in the country? Because the fees we pay are not based on the actual value.

 

HLM: Why does value-based care create so much unease among many providers?

Miller: A lot of the anxiety comes because people don’t have the data. You have to have access to good data and in most cases healthcare providers can’t do that. Medicare has only just recently started to release data, so that someone could actually do the kind of analysis that I recommend in my report.

Most health plans treat their data as a proprietary secret, but there are a number of communities around the country that have multi-payer claims databases where people can do these kinds of analyses.

HLM: Why should providers welcome the switch to value-based care?

Miller: You could actually do better in a value-based payment model. People have the perception that somehow it is going to be worse, but the sooner you get into it the better you may be able to do because you are able to capture a lot of the value out there now that isn’t being captured.

Rather than staying in fee-for-service and hoping you may get a small increase in fees or that you don’t get a cut in fees, it’s better to ask ‘Can I redesign care in a way that would allow me to be paid significantly more?’

Medicare has done a demonstration that has been operational now for several years called theAcute Care Episode Demonstration that bundled together hospital and physician payments for orthopedic and cardiac procedures and the physicians were able to earn up to 25% more than their standard fee-for-service payments by being able to redesign care and reduce the costs. That is far more of an increase in pay quickly than you could ever get by simply staying in the existing fee-for-service model.

HLM: Who should be at the table when providers build the business case for value-based care?

Miller: Step No. 1 is changing the way care is delivered. It is the physicians on the front lines who have to say ‘Where do we think we are actually doing too much of something we shouldn’t do or that we are not providing good care to the patients?’

 

Then you have to get the COO or the CFO to say ‘Let’s work the numbers.’ Typically, you don’t find those two parts of organizations working together. Doing spreadsheets is not the physicians’ skill and providing care is not the CFO’s skill. But if you can get them to come together, that is where the magic happens.

Payment Reform

You say to physicians ‘Where do you think you could redesign care if somebody gave you the flexibility to be paid differently, to be paid for things that you aren’t being paid for today?’ When I talk to physicians, they all have ideas but nobody asks them.

The typical approach is that physicians say ‘Pay me for these things that you don’t pay me for today.’ The health plan, Medicare, employers or whomever says, ‘Wait a minute. That will increase costs if you are going to be paid for something new.’ If you think it is going to be better, run the numbers to see if it actually will save money. What will you do less of and what will that save?

Get everybody in the room. Get their ideas. Figure out which subset appears to be the most promising. Do the detail work and go to payers to put it in place. If you can show success then that encourages people to do more. Not every case will it be a savings proposition.

Which of those things is there really a business case for, and if there seems to be a business case then let’s do a finer analysis to show that and take it to the payers to say ‘how about a deal here?’ Even if you can’t get the perfect data, using approximate data to at least see if it looks like a business case then tells you which things to focus on.

HLM: How soon could a value-based model see a return on investment?

Miller: For many of these things, the savings can happen very quickly. A lot of what has been done in healthcare has been desirable, but has a long-term payoff. There is a lot of focus on better management of diabetes and hypertension; all very desirable but it doesn’t save a lot of money this year.

 

On the other hand, if you focus on people going unnecessarily to the emergency room and getting unnecessary tests and [you] figure out how to redesign that care, you save money immediately because you are avoiding the unnecessary care. Thirty day re-admissions are a perfect example.

HLM: Who do providers speak with on the payer side?

Miller: The focus will differ. Medicare doesn’t have a whole lot of interest in maternity care, whereas for businesses and Medicaid maternity care is in many cases their biggest expenditures. Everyone is interested in chronic disease. The distinction I make is between the purchaser and the payer. The purchaser in commercial insurance is the employer.

In fact, 60% of commercially insured employees in the country are in self-insured employer plans. The deal you are working out is actually with the employer and not the health plan. All the health plan is doing is processing claims. One of the challenges for commercial health plans is that value-based isn’t necessarily a good business proposition for them. They may have to incur costs to change the payment system, but the savings don’t go to them, they go back to their self-insured accounts.

HLM: What influences will insurance exchanges and consumer-driven healthcare play in the business case for value-based care?

Miller: It could be a potential advantage if different provider organizations get beyond this fairly narrow shared-savings model to the point where they are actually able to take accountability for populations of patients and can price that.

They could go on the exchange and allow people to sign up for this ACO and pick a primary care physician there and work with the coordinated set of docs at a lower cost and higher quality than simply picking a generic health plan. It’s kind of halfway between the traditional HMO/PPO models. You are picking who you want to lead your care. You don’t necessarily have to be limited to once set of docs or have a gatekeeper for everything.


John Commins is a senior editor with HealthLeaders Media. 

 

CIA on FitBit – wearable data security

Awesome quote from th CIA re. gait identification:

If there’s one entity that knows the value of the health data uploaded to these devices, it’s the CIA. Last year, at a data conference in New York, the CIA’s chief technology officer, Ira Hunt, gave a talk on big data. During the discussion, he told the crowd that he carries a Fitbit. “We like these things,” he said. “What’s really most intriguing is that you can be 100% guaranteed to be identified by simply your gait—how you walk.”

 

Are Fitbit, Nike, and Garmin Planning to Sell Your Personal Fitness Data?

Are Fitbit, Nike, and Garmin Planning to Sell Your Personal Fitness Data?

These popular fitness companies say they aren’t selling your info, but privacy advocates and the FTC worry that might change.

—By  | Fri Jan. 31, 2014 3:00 AM GMT

 

Lately, fitness-minded Americans have started wearing sporty wrist-band devices that track tons of data: Weight, mile splits, steps taken per day, sleep quality, sexual activity, calories burned—sometimes, even GPS location. People use this data to keep track of their health, and are able send the information to various websites and apps. But this sensitive, personal data could end up in the hands of corporations looking to target these users with advertising, get credit ratings, or determine insurance rates. In other words, that device could start spying on you—and the Federal Trade Commission is worried. 

“Health data from [a woman’s] connected device, may be collected and then sold to data brokers and other companies she does not know exist,” Jessica Rich, director of the Bureau for Consumer Protection at the Federal Trade Commission, said in a speech on Tuesday for Data Privacy Day. “These companies could use her information to market other products and services to her; make decisions about her eligibility for credit, employment, or insurance; and share with yet other companies. And many of these companies may not maintain reasonable safeguards to protect the data they maintain about her.”

Several major US-based fitness device companies contacted by Mother Jones—Fitbit, Garmin, and Nike—say they don’t sell personally identifiable information collected from fitness devices. But privacy advocates warn that the policies of these firms could allow them to sell data, if they ever choose to do so.

Let’s start with the popular Fitbit. When you buy one of these bracelets or clip-on devices, you have the option of automatically sending fitness data to the Fitbit website. And the site encourages you to also submit other medical information, such as blood pressure and glucose levels. According to Fitbit’s privacy policy, “At times Fitbit may make certain personal information available to strategic partners that work with Fitbit to provide services to you.” Stephna May, a Fitbit spokesperson, says that the company “does not sell information collected from the device that can identify individual users, period.” However, she says that the company would consider marketing “aggregate information” that cannot be linked back to an individual user—which is outlined in the privacy policy as aggregated gender, age, height, weight, and usage data. (This is similar to whatFacebook does.)

Nike, which makes the Nike + Fuel Band, says in its privacy policy that the company may collect a host of personal information, but doesn’t say that it can be shared with advertising companies. Joy Davis Fair, a Nike spokesperson, says that the company, “does not share consumer data” with outside advertisers, but selectively shares it with other companies under the Nike’s corporate umbrella, including Converse and Hurley. Garmin’s policy says that users have to consent in order for the company to sell personal information. A Garmin spokesman says the company doesn’t sell personal or aggregated information to advertisers, and doing so isn’t part of the company’s business model. (Polar Flow, which makes the Polar Loop band, is the only company with a privacy policy that explicitly says it won’t sell personally identifiable data for advertising. It is based in Finland and subject to stringent European Union privacy laws.)

Jeffrey Chester, executive director for the Center for Digital Democracy, says that these privacy policies are so broad that they could allow the companies to sell health data—even if they aren’t doing so now. “When companies promise that they aren’t selling your data, that’s because they haven’t developed a business model to do so yet,” Chester says.

Scott Peppet, a University of Colorado law school professor, agrees that companies like Fitbit will eventually move toward sharing this data. “I can paint an incredibly detailed and rich picture of who you are based on your Fitbit data,” he said at a FTC conference last year.“That data is so high quality that I can do things like price insurance premiums or I could probably evaluate your credit score incredibly accurately.”

Even if the companies that make these devices aren’t selling the data, there is another potential privacy concern. Users can send their data to dozens of third-party fitness apps on their phone. Once users do that, the data becomes subject to the privacy policies of the app companies, and these policies do not afford much protection, according to the Privacy Rights Clearinghouse. The group examined 43 popular health and fitness apps last year, and found that, “there are considerable privacy risks for users.” A spokesperson for the FTC told Mother Jones that “fitness devices often work by having apps associated, and [Privacy Rights Clearinghouse’s] analysis here may be relevant.”

If there’s one entity that knows the value of the health data uploaded to these devices, it’s the CIA. Last year, at a data conference in New York, the CIA’s chief technology officer, Ira Hunt, gave a talk on big data. During the discussion, he told the crowd that he carries a Fitbit. “We like these things,” he said. “What’s really most intriguing is that you can be 100% guaranteed to be identified by simply your gait—how you walk.”

 

Overweight or obese now normal

Heart Foundation lays it all down… we need to lose a combined 120million KGs to return to normal healthy weight range… not as easy as it sounds.

http://www.medicalobserver.com.au/news/being-overweight-or-obese-now-the-norm

Being overweight or obese now the norm

AUSTRALIANS need to lose a combined 120 million kilograms to return to a healthy weight range.

The average Australian man now weighs 85.9kg – that’s 6.5kg heavier than he was in 1989 – according to a National Heart Foundation analysis on the severity of the nation’s weight problem.

A breakdown of Heart Foundation national health surveys and government data also revealed that the average woman has gained 5.7kg in the past 25 years and now tips the scales at 71.1kg.

The Heart Foundation’s national director of cardiovascular health, Dr Rob Grenfell, said two-thirds of Australians now fall outside the healthy weight range, with nearly half a million people morbidly obese (BMI > 40).

“To return to a healthy weight range, an average man would need to lose 8.9kg and a woman would need to lose 5.7kg,” Dr Grenfell said.

“The combined weight loss required is just short of 120 million kilograms across the nation.”

The analysis highlights that the average BMI for men is up from 25.3 to 27.9 since 1989, and the average for women is up from 24.3 to 27.2.

Obesity has increased from 8.4% of the population in 1980, to 28.3% in 2011–12.

“It’s scary that two in three Australians are now above the healthy weight range, making overweight and obese weight ranges more ‘normal’ than healthy,” he said.

“The healthiest BMI is relatively lean, at around 22.5–24.9, which is equivalent to a weight of 70–77kg for an Australian man of average height and 59–65kg for an Australian woman of average height.”

In comparison to 1980, the proportion of obese adult Australians has tripled, while the number of people in the healthy weight range has almost halved.

WA and Queensland now have the highest average male BMIs at 28.2, according to the Australian Health Survey of 2011/12, with the highest average female BMIs, 27.7, occurring in SA and Tasmania.

Victoria has the lowest average BMIs at 27.6 for men and 26.9 for women.

Genomics improves cancer treatment response by 21 months

  • COXEN (CO-eXpresssion gENe analysis), allowed the researchers to identify the heterogeneity and genetic signatures of tumours that responded to each drug.

 

http://www.medicalobserver.com.au/news/lives-extended-by-genetic-algorithm

Lives extended by genetic algorithm

A GENETIC modelling algorithm that predicts patient response to three standard chemotherapy drugs used to treat ovarian cancer could extend patients’ lives by 21 months.

A retrospective study used data from an ovarian cancer registry to genetically profile over 3000 ovarian tumour samples from patients already on one of three common ovarian cancer drugs – paclitaxel, cyclophosphamide and topotecan – to discover differences between tumours that responded to treatment and tumours that didn’t.

The Canadian researchers said site-specific cancers have traditionally been considered to be homogenous, but increasingly, evidence is pointing to significant heterogeneity within the disease.

They also noted that “because it has been so difficult to predict which ovarian cancers will respond to each of the three available drugs, doctors have largely been forced to guess which will work best”, which can lead to treatment failure.
The model, called COXEN (CO-eXpresssion gENe analysis), allowed the researchers to identify the heterogeneity and genetic signatures of tumours that responded to each drug.

They were also able to show that patients who had, by chance, been given the drug that the COXEN model would have picked for them lived 21 months longer than patients who had been initiated on a different drug.

The researchers said their study shows that biomarker-based personalised chemotherapy selection could improve survival of patients with advanced ovarian cancer.

While the model would need to be validated with a prospective clinical trial before use in a clinical setting, the authors said that COXEN led to similar results in patients with bladder cancer in a previous study.

A prospective clinical trial of COXEN in bladder cancer is underway.

PLOS One 2014; 5 February

WSJ Transparent Pricing

  •  One of the most widespread initiatives comes from insurers themselves—who say they are eager to help plan members and employers cut their health-care bills. Some 98% of health plans now offer their members some online tool that lets them calculate their out-of-pocket costs, according to a survey by Catalyst for Payment Reform. A few let users compare different providers in the same network.
  • UnitedHealth Group Inc. has one of the most extensive tools. More than 21 million members can log into myHealthcare Cost Estimator and compare the negotiated rates for more than 500 individual services at in-network providers across the country, as well as their individual out-of-pocket costs for each one. Hundreds of thousands of plan members have used the tool since it launched in 2012, the company says.
  • In one pilot project, the California Public Employees’ Retirement System, found prices for hip and knee replacements ranging from $15,000 to $110,000 in the San Francisco area. It agreed to pay up to $30,000, and some 40 hospitals cut their prices to match. Such initiatives have helped Calpers save nearly $3 million in the past two years, one study found.
  • A growing body of research has found that there is no clear connection between price and outcomes such as mortality rates, blood clots, bed sores and hospital readmission. “Until you break that connection in peoples’ minds, there is a perverse incentive for hospitals and health systems to continue to raise prices,” Ms. Dentzer says.

http://online.wsj.com/news/articles/SB10001424052702303650204579375242842086688

How to Bring the Price of Health Care Into the Open

There’s a Big Push to Tell Patients What They’ll Pay—Before They Decide on Treatment

It’s a simple idea, but a radical one. Let people know in advance how much health care will cost them—and whether they can find a better deal somewhere else.

With outrage growing over incomprehensible medical bills and patients facing a higher share of the costs, momentum is building for efforts to do just that. Price transparency, as it is known, is common in most industries but rare in health care, where “charges,” “prices,” “rates” and “payments” all have different meanings and bear little relation to actual costs.

Unlike other industries, prices for health care can vary dramatically depending on who’s paying. The list prices for hospital stays and doctor visits are often just opening bids that insurers negotiate down. The deals insurers and providers strike are often proprietary, making comparisons difficult. Even doctors are generally clueless about what the tests, drugs and specialists they recommend will cost patients.

Princeton economist Uwe Reinhardt likens using the U.S. health-care system to shopping in a department store blindfolded and months later being handed a statement that says, “Pay this amount.”

The price-transparency movement aims to lift that veil of secrecy and empower patients and other payers to be smarter health-care consumers. Federal and state agencies are gathering reams of price information from doctors and hospitals and posting them for the public. Health plans are offering online tools that let members calculate their out-of-pocket costs. Startup companies are ferreting out and publishing the long-secret rates that providers negotiate with insurers.

When consumers can compare prices for doctor visits, hospital stays and other services, the theory goes, market competition will help keep them down.

An Incentive to Change

This is new territory for health care. Doctors and hospitals have rarely competed on cost. Third-party payers still foot the bulk of the bills, and many players in the health-care industry benefit from keeping their costs and profit margins murky.

“The time for transparency has clearly arrived—but is everybody ready to have real pricing power brought to bear in a way that could destabilize the health-care sector?” asks Susan Dentzer, a senior policy adviser at the Robert Wood Johnson Foundation. “It means upsetting a lot of apple carts.”

The pressure to change is rising, however. Experts expect consumers to be much more price-sensitive as they shoulder a growing proportion of health costs themselves. Last year, 38% of Americans with employer-sponsored insurance had a deductible of $1,000 or more—up from 10% in 2006, according to the Kaiser Family Foundation.

Silver and bronze plans created by the Affordable Care Act carry average family deductibles of $6,000 and $10,386, respectively. More than half of bronze plans also require patients to pay 30% of doctors’ fees, according to health-information site HealthPocket.com. “Most of us still don’t have much financial incentive to shop around for cheaper care,” says Suzanne Delbanco, executive director of Catalyst for Payment Reform, a nonprofit that works on behalf of employers. “That’s changing rapidly.”

 

Efforts to raise transparency are coming from a number of corners, including the Obama administration. But some have mainly shown how confusing health-care pricing is.

Hoping to shine a light on the variations in hospital charges, the Centers for Medicare and Medicaid Services, or CMS, grabbed headlines last May when it released a list of the average prices 3,300 U.S. hospitals charged Medicare for the 100 most common inpatient services during 2011.

Huge Differences

The variations were stunning. The average charge for joint-replacement surgery, for example, ranged from $5,300 in Ada, Okla., to $223,000 in Monterey Park, Calif. Even in the same city, there were huge swings. The charge for treating an episode of heart failure was $9,000 in one hospital in Jackson, Miss., and $51,000 in another.

A month later, CMS released a second database comparing average hospital charges for 30 common outpatient procedures, and the variations were just as great. A hospital in Pennington, N.J., charged $3,036 for a diagnostic and screening ultrasound, while one in Bronx, N.Y., billed just $88.

Many hospital executives dismiss those list prices—also known as chargemaster prices—as meaningless and misleading, since few patients ever pay them. Commercial insurers often use them as a starting point for negotiating big discounts. Medicare itself pays hospitals predetermined rates based on diagnoses, regardless of what they charge.

Industry experts say list prices vary so much in part because hospitals use different accounting methods and have different patient populations. List prices also reflect all the costs of running a hospital, including keeping ERs, burn units and other costly services running 24 hours a day. What’s more, many hospital executives say they have to mark up charges for privately insured patients because Medicare and Medicaid reimbursements don’t cover those patients’ cost—a shortfall the American Hospital Association puts at $46 billion nationwide last year.

Hospitals “are absolutely in favor of price transparency,” says AHA president Rich Umbdenstock, and they support a bill in Congress that would let individual states determine price-disclosure rules. He also says hospitals would like to end the confusing chargemaster and cost-shifting practices, but they can’t do it without big changes in payment practices by both the government and the insurance industry.

“If this were in our power to solve, we would have done it a long time ago,” Mr. Umbdenstock says. “But it’s not something we can do on our own.”

Shining a Light

Jonathan Blum, deputy administrator of the CMS, counters that chargemaster prices do matter, particularly to uninsured patients who sometimes get stuck with those inflated bills. He says the administration’s goal was to spark discussion about price variations, and that “a tremendous number” of visitors had downloaded the data.

“We’ve discovered that oftentimes, even health-care providers don’t fully realize the extent of those variations,” he says. “Our hypothesis is that a lot of the variations aren’t warranted.”

The prices insurers negotiate with hospitals and doctors are more important to consumers, experts say. Traditionally, those rates have been proprietary. Neither insurers nor providers want competitors and other business partners to know what they’re willing to settle for. Some contracts include gag clauses barring disclosure.

But states are increasingly requiring payers and providers to reveal that information. A few states specifically outlaw gag clauses in health-care contracts. Sixteen states have “all-payer claims databases” designed to collect insurance claims data and use it to monitor trends and identify high- and low-price providers. And some 38 states now require hospitals to report at least some pricing information, although only two—Massachusetts and New Hampshire—rated an “A” in Catalyst for Payment Reform’s annual report card for making the information accessible and usable by patients.

Meanwhile, entrepreneurs are sleuthing out negotiated rates from claims data and making them available to consumers and employers in various forms. Healthcare Bluebook aims to do for health care what the Kelley Blue Book does for used cars: It analyzes negotiated rates paid for thousands of medical services in every ZIP Code—supplied by employers and other clients—and posts what it considers a “fair” price for each so consumers can evaluate what they’re being charged.

Bluebook’s founder and CEO, Jeffrey Rice, says the rates insurers pay for, say, an MRI or knee surgery can vary as much as chargemaster prices do, particularly if a local hospital is dominant or prestigious.

“The difference may not be much between Nashville and Chicago—the big difference may be just down the block,” he says.

Mr. Rice says the employers Healthcare Bluebook works with have saved as much as 12% on their health-care costs by making price information available to their employees, with most savings coming on imaging studies, endoscopies, cardiac testing and other outpatient procedures.

Another service, PricingHealthcare.com, asks users to anonymously supply information from their own medical bills to help it amass the list prices, cash prices and negotiated rates for common procedures. It currently shows rates for some 500 procedures in 11 states. Founder Randy Cox says some providers are furious when asked what their rates are, while others are eager to have their entire price list posted. “I get calls from hospital CEOs who know people are concerned about price and think this is an opportunity for their business,” he says.

A Hand From Insurers

One of the most widespread initiatives comes from insurers themselves—who say they are eager to help plan members and employers cut their health-care bills. Some 98% of health plans now offer their members some online tool that lets them calculate their out-of-pocket costs, according to a survey by Catalyst for Payment Reform. A few let users compare different providers in the same network.

UnitedHealth Group Inc. has one of the most extensive tools. More than 21 million members can log into myHealthcare Cost Estimator and compare the negotiated rates for more than 500 individual services at in-network providers across the country, as well as their individual out-of-pocket costs for each one. Hundreds of thousands of plan members have used the tool since it launched in 2012, the company says.

Nationwide, only about 2% of health-plan members who have access to such tools have used them, according to Catalyst for Payment Reform. But Ms. Delbanco expects that number to rise as more patients become aware of the tools and see their out-of-pocket costs growing.

Proponents say it is too early to tell how much impact transparency efforts will have on costs overall. California has required hospitals to make their chargemaster prices public since 2003, with little effect on prices.

But one approach called “reference pricing” has yielded some savings. Where local prices differ substantially for a service like a colonoscopy, an insurer publishes a list of providers’ rates and agrees to pay a set amount. If patients choose a provider that charges more, they must pay the difference themselves.

In one pilot project, the California Public Employees’ Retirement System, found prices for hip and knee replacements ranging from $15,000 to $110,000 in the San Francisco area. It agreed to pay up to $30,000, and some 40 hospitals cut their prices to match. Such initiatives have helped Calpers save nearly $3 million in the past two years, one study found.

What Comes Next?

Experts say that as consumers increasingly compare prices, it’s critical to provide them with information about quality of care as well—otherwise, they might assume high cost equates with high quality.

A growing body of research has found that there is no clear connection between price and outcomes such as mortality rates, blood clots, bed sores and hospital readmission. “Until you break that connection in peoples’ minds, there is a perverse incentive for hospitals and health systems to continue to raise prices,” Ms. Dentzer says.

Indeed, critics fear that some price-transparency efforts could backfire and spur higher prices: If providers see that insurers are paying competitors more, they might hold out for higher rates, and insurers might be less inclined to give some providers favorable deals.

Some skeptics think that without fundamental changes in how health care is priced and paid for, transparency may confuse consumers more than it empowers them.

But there’s a growing consensus that while price transparency alone cannot transform the health-care system, it is necessary to help reveal which costs are excessive and let consumers make better-informed choices.

“At the end of the day, it’s our money,” Ms. Delbanco says. “We have a right to know what our health care is going to cost.”

Ms. Beck covers health care and writes The Wall Street Journal’s Health Journal column. She can be reached at melinda.beck@wsj.com.

Katz on breast cancer

Good, solid advice on appropriate screening, prevention and detection of breast cancer.

>> check the credentials of the radiologist reviewing the films!

Can We Unmuddle Mammography?

February 20, 2014

new study of mammography, showing lack of survival benefit, has once again muddied these waters and muddled the relevant messaging. The study, generating considerable controversy, as has much prior research on the topic, looked at breast cancer mortality over a 25 year period in nearly 90,000 Canadian women assigned to mammography or usual medical care without mammography during the initial 5 years of the study period. There was no appreciable difference between groups.

Perhaps you see a major problem already. To study the effects of mammography, or any cancer screening, on mortality over time requires…time. Time goes by at its customary pace no matter the research goals. So, if it takes 25 years to get the desired data, the intervention needed to take place 25 years ago. And so, inescapably, this study is entirely blind to any advances in mammography technique, technology, or interpretation over the last 20 years at least. In medicine, two decades is just about forever.

Perhaps the value of mammography is perennially muddled- if just a bit less so than prostate cancer screening– for the most obvious of reasons. The truth is in the middle, between slam-dunk and fuhggeddaboudit. With the apparent exception of titillating (if not salacious) novels, we don’t tend to like shades of gray. But that’s where mammography falls; it’s pretty close to a toss-up.

There is a long history of research on the topic, and conclusions have been anything but consistent. Some studies suggest clear potential benefit for women who would not otherwise be screened. But, of course, women who would not be screened are apt to differ in a variety of ways from those who would- including, perhaps, their access to, and the quality of, primary medical care. Unbundling such influences is nearly impossible.

But, if, instead, you attempt to study women who would be screened anyway, how do you randomize them to a control group? What woman, inclined to get mammograms, would go without for 20 years for the sake of a clinical trial? Not very many I know.

Enrollment in a trial itself can exert an influence. Regardless of assignment to mammogram or control, there may be more attention to breast health and a greater likelihood of finding breast cancer early among all women participating in a study. This effect obscures any real world, and potentially important differences between intervention and control arms.

We are, as well, dependent on an imperfect technology. Even if finding breast cancer early through imaging is decisively beneficial, studies will produce variable results based on flawed imaging, variable performance of the same technology in different women, and variation in the quality of interpretation of mammograms. That much more so when today’s data are the product of mammography done 20 to 25 years ago. There have been improvements in scans, scanners, and the training of radiologists during that span.

And complicating things further, mammography is a source of radiation, and may be doing some direct harm as well as good.

The false positive error rate of mammography is notoriously high, and unavoidably so if we want to avoid false negatives. False positives occur when we think we’ve found cancer that isn’t there. It can be avoided by raising the bar, but then there is a risk of missing cancers that are there. We tend to favor the former error over the latter, and in the absence of perfect tests, are forced to choose.

We may have failed to translate good evidence into practice. Pre-menopausal mammography would likely be more useful if performed more than once a year. Breast cancer tends to be more aggressive and progress faster in younger women. Post-menopausal mammography might be just as useful done every other year. A one-size-fits-all approach may attenuate benefit and raise the rates of harm to both groups.

And then, perhaps most important: not all the trouble we find through screening deserves the attention it gets. Some tiny breast cancers, like the majority of prostate cancers, are destined to do nothing if just left alone. These are cases where cure is very likely to be worse than disease- but we are not good yet at differentiating. Doing so requires analysis at the level of histopathology (i.e., tissue and cell analysis), and molecular genetics. This can be done, but it’s not routine and our abilities in this space remain limited.

One very important issue routinely ignored when parsing the benefits of any cancer screening modality, mammography included, is that screening does not prevent cancer. The goal of screening is to find cancer early- which is generally much better than finding it late. But it’s not nearly as good as not getting it in the first place. The evidence is strong that optimal lifestyle practices can slash risk for all major chronic diseases, cancer included. Related evidence shows that lifestyle as medicine can modify gene expression in a manner projected to protect against cancer development, and progression. DNA is not destiny; dinner may be! There isinteresting literature on the relevant timing as well. It may be the best way to improve breast cancer in women is to focus on healthy living in childhood. That we could dramatically lower rates of cancer overall by living well across the life span is all but undisputed.

There are many reasons why decisive evidence that mammography confers net survival benefit at the population level, or that it lacks benefit and should be abandoned – is elusive. The result is something of a muddle for epidemiology. Until technology, interpretation, application, and histopathological confirmation all rise to consistently high standards, we can’t unmuddle mammography for populations.

But by combining what we know about the test with what you and your doctor know about you, a basis for a good decision should be at hand. Inquire about the technology, making sure it is state of the art. Ask about the training of the radiologist reading the film. Ask as well about plans for immediate next steps if the mammogram is abnormal. Good breast care centers follow up right away with additional testing to differentiate false from true positives. Ask whether screening has been personalized- taking into account your age, breast density, family history, and risk profile.

Evidence-based recommendations about mammography for the population at large where one size must fit all are, for now, ineluctably muddled. By personalizing the decision, as good clinical medicine always should, we can, I believe, unmuddle things for you.

-fin

Lethal but Legal

Thanks Marion. Another book to chase up…

Reading for the weekend: Lethal But Legal

Reading for the weekend: Lethal But Legal

Nick Freudenberg.  Lethal but Legal: Corporations, Consumption, and Protecting Public Health.  Oxford, 2014.

Lethal But Legal

 

I spoke last night on a panel celebrating the release of this book.  I gave it a rave blurb:

Lethal But Legal is a superb, magnificently written, courageous, and thoroughly compelling exposé of how corporations selling cigarettes, guns, cars, drugs, booze, and food and beverages enrich themselves at the expense of public health.  Even more important, Freudenberg tells us how we can organize to counter corporate power and achieve a healthier and more sustainable environment.  This book should be required reading for anyone who cares about promoting health, protecting democratic institutions, and achieving a more equitable and just society.

I will be using this one in classes.  Congratulations to Nick Freudenberg, director of Hunter College’s Food Policy Center, for producing this distinguished work of scholarship.

Partnership for a Healthier America Innovation Challenge

Nicholas Gruen put me on to this effort… so impressed to see these efforts emerge in such a can do endeavour and with the first lady giving the welcoming address.

http://govfresh.com/event/partnership-healthier-america-innovation-challenge/

Partnership for a Healthier America Innovation Challenge

Event Navigation

A gathering of business, government and non-profit visionaries, the Building a Healthier Future Summit focuses on action over talk. The PHA Innovation Challenge offers a unique opportunity to realize the event’s mission of creating bold, tangible and actionable solutions using the most powerful tool available – technology. This year, Partnership for a Healthier America (PHA) is working with The Feast to engage the most talented innovators and makers in technology and design to help solve the childhood obesity epidemic.

PHA is hosting a hackathon in the lead-up to the conference, when participants will prototype and build working solutions focused on the theme of Childhood Obesity. The hackathon will explore two opportunities within the challenge of Childhood Obesity:

  1. To help teachers empower students to make healthy choices about the food they consume, whether at home or at school.
  2. To create an information avenue that shows families the healthy food options and physical activity opportunities available locally.

PHA and The Feast are recruiting a group of the best designers, developers, stakeholders and entrepreneurs to create solutions that will help make the healthy choice the easy choice. Over two dedicated workdays the weekend prior to the Summit, participants will form teams to work on one of the two opportunities. Participants will receive support from subject matter experts and mentors in crafting their solutions while partaking in exciting activities and enjoying healthy meals. The following week, all the participating hackers will receive free admission and full access to PHA’s Building a Healthier Future Summit, with the opportunity to engage with innovators in the health sector. Two winning teams will then take the stage at Summit to present their work to an audience of 1,000 industry leaders, with one team winning an audience choice award.

PHA believes that change happens when anyone is empowered to re-imagine how something might be better and seizes the opportunity to realize that vision.

Details

Start:
End:
March 9, 2014 5:00 pm
Event Category:
Event Tags:
Website:
http://ahealthieramerica.org/summit/innovation/

Organizer

Partnership for a Healthier America
Website:
http://ahealthieramerica.org

Venue

Partnership for a Healthier America
2001 Pennsylvania Ave. NW Suite 900,Washington, DC, 20006 United States

+ Google Map

Website:
http://http://ahealthieramerica.org/

if we approached drowning like obesity, we would go looking for those genes

It is equally true that the sinking of the Titanic did not affect all passengers equally. More generally, falling into water does not affect all human beings equally. Some of us know how to swim, and some do not. Some of us can hold our breath longer than others.

==

Imagine that these pioneers were intrigued by the sea, and therefore boldly wandered in. Having no experience with matters maritime, and knowing nothing about swimming, several of them drowned. Several others nearly drowned, but managed to climb out in the nick of time.

And then imagine, rather than reaching any fundamental conclusions about the interactions of their kind with large bodies of water, these sagacious people scratched their extra-terrestrial heads and said something like (in whatever language they speak): “When we wander into that enormous puddle, some of us die and some of us don’t. Clearly, then, there must be variation in our go-forth-into-enormous-puddle genes. Let us study our genes and look for that variation so we may better understand what happened here today. Then, perhaps, we might find a way to fix the go-not-into-great-puddles-or-you-will-surely-drown genes, as those must be defective. After all, a few of us went into the big puddle and lived. Surely there must be some way for us all to have those wonderful you-will-only-almost-die-if-you-go-into-great-puddle genes. ”

==

Human beings don’t have gills, and there are genes to blame. But the right response looks like swimming lessons, and lifeguards, and fences around pools- not studying genes while pushing kids into the surf. Not a new pill to fix an age-old part of who we are that was never really broken.

 

http://www.linkedin.com/today/post/article/20140219143107-23027997-gills-pills-and-obesity-genes

Gills, Pills, and Obesity Genes

February 19, 2014

Two new studies, just published on-line in JAMA Pediatrics, may have us fired up yet again about the genetic variation to blame for obesity. But then again, is that really the problem?

One of the studies examined variation in food and satiety responses, which we may summarize as appetite, in roughly 400 pairs of 3-month-old twins in the U.K., and tracked growth and development over time. There are always lots of important details in biomedical research, but the perhaps predictable punch line was this: the babies with the heartier appetites gained the more weight.

The second study was directed at the same basic issue, but went a bit deeper. Investigators again examined the association between appetite and weight gain in a group of over 2000 twin children in the U.K., but this team included an assessment of genes associated with variation in satiety responses, essentially how much eating it takes to feel full. Once again, more appetite meant more weight gain. But this time, more genes for more appetite was identified as the real culprit.

Finally, an accompanying editorial noted the importance of this kind of genetic research because the obesigenic environment “does not affect all children equally.”

That is undeniably true. It is equally true that the sinking of the Titanic did not affect all passengers equally. More generally, falling into water does not affect all human beings equally. Some of us know how to swim, and some do not. Some of us can hold our breath longer than others.

And while there is, I am quite confident, genetic variability we could find and associate with variation in how long we can hold our breath, I am not sure how illuminating that would truly be about the risk of drowning.

Human beings are vulnerable to drowning because we don’t have gills, and the reason absolutely resides in our genes. We have Homo sapien genes that include the recipe for lungs, and exclude the recipe for gills. In contrast, blue fin tuna and guppy genes reliably include the recipe for gills and exclude the recipe for lungs. Blue fin tuna and guppies have just the kind of trouble out of water that we are prone to have in it. We don’t have gills because we aren’t fish- and fish don’t have lungs because they aren’t people. And in both cases, the reason we aren’t them and they aren’t us resides in our respective genes.

Given that, if we approached drowning like obesity, we would go looking for those genes. We would, readily, find the divergences between human and guppy genes. And we might, I suppose, declare that a genetic basis for drowning had been identified. And once genes were indicted for drowning, we could head off down the path of drug development or genetic engineering to deal with the problem.

Hold that thought, if not your breath, and let’s probe the corresponding depths.

Imagine a people on some imaginary world that lived on a great landmass, far from any body of water, evolving and adapting accordingly throughout their long history. Then imagine that, after however many eons in their native land-locked state, and for reasons we may ignore or guess at, these people set off on an excursion, and encounter the sea for the first time. They knew water, of course-because they drank it like we do; but they had never before seen any body of water larger than a puddle.

Imagine that these pioneers were intrigued by the sea, and therefore boldly wandered in. Having no experience with matters maritime, and knowing nothing about swimming, several of them drowned. Several others nearly drowned, but managed to climb out in the nick of time.

And then imagine, rather than reaching any fundamental conclusions about the interactions of their kind with large bodies of water, these sagacious people scratched their extra-terrestrial heads and said something like (in whatever language they speak): “When we wander into that enormous puddle, some of us die and some of us don’t. Clearly, then, there must be variation in our go-forth-into-enormous-puddle genes. Let us study our genes and look for that variation so we may better understand what happened here today. Then, perhaps, we might find a way to fix the go-not-into-great-puddles-or-you-will-surely-drown genes, as those must be defective. After all, a few of us went into the big puddle and lived. Surely there must be some way for us all to have those wonderful you-will-only-almost-die-if-you-go-into-great-puddle genes. ”

Gazing at these counterparts across the cosmos, they look rather like nincompoops, don’t they?

I am not refuting the value in these new studies. The editorialist very appropriately notes that early identification of genetic vulnerability to weight gain might allow for very early implementation of prevention strategies, so that obesity does not develop in the first place.

I like that- but do we really need maps of our kids’ genomes to take such action? We havepandemic childhood obesity right now-meaning legions of kids around the world are vulnerable to weight gain, whatever their genes. And yet, we routinely feed them junk. We routinely jettison physical activity from their daily routines. We peddle to them foods willfully designed to be irresistible if not addictive, and to maximize the number of calories it takes to feel full. Can we really justify the lunacy of a culture that studies genes looking for variation in satiety responses, while engineering foods to undermine satiety responses?

Yes, our genetic vulnerability to obesity is variable- much, I bet, like our genetic vulnerability to drowning. But I don’t think that invites a genetic study of the drowning victims of the Titanic. I think the bigger issue was the obvious one: the ship went down.

We are all in the same boat, and it’s sinking, too- as evidence by a global rise in bariatric surgery for ever younger children. The genes underlying vulnerability to obesity in all their variation were there a generation or two or twenty ago, too- when childhood obesity was rare. Those same genes are there now that it is rampant. Knowledge of them may be put to good use, but not if it distracts us from the sinking ship. What has changed is not within our children, but all around them. And we don’t need to wait for a genetic map of each child to fix it.

Human beings don’t have gills, and there are genes to blame. But the right response looks like swimming lessons, and lifeguards, and fences around pools- not studying genes while pushing kids into the surf. Not a new pill to fix an age-old part of who we are that was never really broken.

-fin

Google gunning for the end of death…

Terrific summary of the state of play.

British gerontologist Aubrey de Grey believes achieving human immortality is inevitable. Last October de Grey told the audience at a US technology conference that they could expect to live 1000 years, maybe longer.

 

http://thenewdaily.com.au/life/2014/02/11/medical-science-close-curing-death/

Could medical science be close to curing death?

8:49pm, Feb 11
MICHELLE HAMER
If you were given the chance, would you choose to live forever, or another few hundred years? It may sound like the stuff of fantasy, but some very smart people are working to make death a thing of the past.
Live forever

Scientists are working to stop the ageing process, and extend the living… Photo: Shutterstock

Nanobots in your blood stream, backing up your brain to a computer, swapping your fallible human form for a sophisticated holographic avatar – it might sound like science fiction, but these are just some of the ways that science is hoping to extend human life and inch us closer to living forever.

US futurist, inventor and Google’s head of engineering, Ray Kurzweil has predicted that by the end of the century humans and machines will merge to create super humans who may never face the prospect of death. And Kurzweil, 65, hopes to be among those kicking mortality to the curb.

Ray Kurzweil

Ray Kurzweil: Working to bring an end to death. Photo: Getty

“Twenty years from now, we will be adding more time than is going by to your remaining life expectancy,” Kurzweil told Forbes Magazine. “We’ve quadrupled life expectancy in the past 1000 years and doubled it in the past 200 years. We’re now able to reprogram health and medicine as software, and so that pace is only going to continue to accelerate.”

Kurzweil is no slouch when it comes to accurate predictions. In the 1980s he predicted the incredible rise of the internet, foresaw the fall of the Soviet Union and identified the year when computers would beat humans at chess.

His next predictions include the programming of nanobots to work from within the body to augment the immune system and fight pathogens. By 2045 he sees us backing up our minds to the cloud and downloading ourselves into robotic forms.

And he’s not the only scientist hoping to blow out hundreds of candles in the future.

Immortality: Not if, when

British gerontologist Aubrey de Grey believes achieving human immortality is inevitable. Last October de Grey told the audience at a US technology conference that they could expect to live 1000 years, maybe longer.

Ageing, he says, is a simple case of bad engineering, and once the human body’s kinks are ironed out we’ll be able to reverse its effects and put death on the back burner.

“My approach is to start from the straightforward principle that our body is a machine. A very complicated machine, but nonetheless a machine, and it can be subjected to maintenance and repair in the same way as a simple machine, like a car,” de Grey has said. “What I’m after is not living to 1000. I’m after letting people avoid death for as long as they want to.”

Google is on board

It’s a goal that even tech giant Google thinks is worth pursuing.

When Google entered the anti-ageing business last year, with the launch of its new biotechnology company Calico, it brought a new level of interest, respectability and crucially – funding – to the field.

Calico has poached some of the leading anti-ageing researchers from across the world to work on the challenge of extending life.

“I think that if Google succeeds, this would be their greatest gift to humanity,” said David Sinclair, an Australian professor of genetics at Harvard Medical School.

Professor Sinclair led a research team which last year announced it had reversed muscle ageing in mice, the results of which exceeded his expectations.

“We want immortality so badly that we’re always ready to be swept away into unthinkingness … Half in love with the impossible we’ve always wanted to conquer death.”

“I’ve been studying ageing at the molecular level now for nearly 20 years and I didn’t think I’d see a day when ageing could be reversed. I thought we’d be lucky to slow it down a little bit,” he was quoted as saying.

“There’s clearly much more work to be done here, but if those results stand, then aging may be a reversible condition, if it is caught early,” he said.

The research involved improving communication between a cell’s mitochondria and nucleus. Mitochondria are like a battery within a cell, powering important biological functions. When communication breaks down between this and the nucleus, the effects of ageing accelerate.

Human trials of the groundbreaking process are expected to start this year.

Buying life

It’s the sort of breakthrough that can’t come soon enough for several  billionaires across the globe who are pouring their fortunes and hopes into immortality research.

Russian entrepreneur, Dmitry Itskov founded the 2045 Initiative in 2011 with the aim of thwarting human death within three decades. Itskov envisages ‘neo-humans’ who will relinquish clunky human forms and adopt sophisticated machine bodies. He claims humans will eventually download their minds into artificial brains, which will then be connected to humanoid robots he calls Avatars.

According to 2045.com: “Substance independent minds will receive new bodies with capabilities far exceeding those of ordinary humans … Humanity will make a fully managed evolutionary transition and eventually become a new species.”

PayPal co-founder Peter Thiel donated $US3.5 million to Aubrey de Grey’s not-for-profit research foundation, telling the New Yorker at the time that: “Probably the most extreme form of inequality is between people who are alive and people who are dead”.

Clearly Thiel would prefer to remain among the living and he’s prepared to pay for his pitch at immortality, most recently making a large donation to the Singularity Institute, which focuses on creating artificial intelligence that could see the rise of cyborgs (merged humans and machines).

Maximising life, minimising death

US entrepreneur turned science innovator, David Kekich, dedicated his life and impressive bank balance to reversing ageing after he was paralysed from a spinal cord injury in 1978. Kekich initially raised money for paralysis research but then switched to anti-ageing research. He founded the Maximum Life Foundation in 1999 and aims to reverse human ageing by 2033.

On his website Kekich writes: “We are moving from an era in which nothing could be done to defeat ageing into an era in which advancing biotechnology will give us the tools to do overcome it … Now, at the dawn of the biotechnology era, the inevitable is no longer inevitable. The research establishment – if sufficiently funded and motivated – could make spectacular inroads into repairing and preventing the root causes of ageing within our lifetime.”

But given that there are yet to be any proven means for extending human life, these billionaires may be motivated more by ego than altruism.

As US author Adam Leith Gollner writes in The Book of Immortality: the Science Belief and Magic Behind Living Forever (Sribner 2013): “We want immortality so badly that we’re always ready to be swept away into unthinkingness … Half in love with the impossible we’ve always wanted to conquer death.”

Yet he says all humans can really do to live longer is to eat well and exercise.

“We all have to go … whether dying in battle, tumbling off a horse, succumbing to pneumonia or being shivved by a lover. Maybe one day we just don’t wake up. However it happens, we enter the mystery.”